Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672016 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
A Phase 3 study of Female Contraception, sponsored by Mylan Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
- 20
- Study locations
NCT06672016: Recruiting Phase 3 study of Female Contraception, sponsored by Mylan Pharmaceuticals.
NCT06672016 is a Phase 3 study of Female Contraception that is actively recruiting participants, run by Mylan Pharmaceuticals. The registered enrollment target is 1,500 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06672016, a Phase 3 study of Female Contraception, is actively recruiting participants, sponsored by Mylan Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a transdermal system that contains the active ingredient, progestin.
Primary Outcome
The primary efficacy endpoint will be pregnancy rate described by Pearl Index (PI). PI is defined as the number of pregnancies per 100 women-years.
Conditions Studied
Interventions
- DRUG Transdermal system containing progestin
Study Locations (20)
Florida
- AMR Fort Myers - Fort Myers
- Altus Research - Lake Worth
- OB GYN Associates of Mid Florida P.A. - Leesburg
- Genoma Research Group - Miami
- Spotlight Research Center - Miami
- New Age Med Research Corp - Miami
- Sensible Healthcare, LLC - Ocoee
- Innovation Medical Research Center - Palmetto Bay
- Clinical Research Center of Florida - Pompano Beach
Alabama
- Alabama Clinical Therapeutics, LLC - Birmingham
- SEC Clinical Research - Dothan
- AMR Mobile - Mobile
- Velocity Clinical Research - Mobile
California
- Velocity Clinical Research Santa Ana - Huntington Park
- Essential Access Health - Los Angeles
- Women's Health Care Research Corp - San Diego
- WR-Medical Center For Clinical Research - San Diego
Arizona
- Velocity Clinical Research - Phoenix
- Precision Trials - Phoenix
Georgia
- CenExel iResearch LLC - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2027-04 |
| Phase | Phase 3 |
What NCT06672016 shows while recruiting
NCT06672016 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher).
The record links to 1 condition, with Female Contraception appearing as the primary indexed condition, and to 1 intervention - of which Transdermal system containing progestin is the first listed.
NCT06672016 names 20 study sites across 5 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT06672016 about?
NCT06672016 is a clinical study titled "Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential". The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a trans...
What is the current status of trial NCT06672016?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2025-01-13. Estimated completion is 2027-04.
What conditions does trial NCT06672016 study?
This clinical trial studies the following conditions: Female Contraception.
What interventions are being tested in trial NCT06672016?
The interventions under investigation include: Transdermal system containing progestin (DRUG).
Who is sponsoring clinical trial NCT06672016?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672016 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Female Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06672016's enrollment target sits among peer trials
1,500 158th of 2000 higher than 1,839 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI